发明名称 |
Antibody against the CSF-1R |
摘要 |
The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions. |
申请公布号 |
US9428584(B2) |
申请公布日期 |
2016.08.30 |
申请号 |
US201313896932 |
申请日期 |
2013.05.17 |
申请人 |
Transgene S.A. |
发明人 |
Haegel Hèléne;Thioudellet Christine;Geist Michel;Grellier Benoît;Marchand Jean-Baptiste |
分类号 |
C07K16/00;C12P21/08;C07K16/28;A61K39/00 |
主分类号 |
C07K16/00 |
代理机构 |
Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P. |
代理人 |
Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P. |
主权项 |
1. An isolated, recombinant or purified antibody that specifically binds to human CSF-1R, wherein
(i) it comprises:
(a) a heavy-chain variable region being defined by the following formula
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4wherein:FR1, FR2, FR3, and FR4 are each framework regions;CDR1, CDR2, and CDR3 are each complementarity determining regions;wherein:CDR1 has at least five consecutive amino acids of the sequence starting in position 45 and finishing in position 54 of SEQ ID NO:2, wherein said at least five consecutive amino acids include SEQ ID NO:11;CDR2 has at least five consecutive amino acids of the sequence starting in position 66 and finishing in position 87 of SEQ ID NO:2, wherein said at least five consecutive amino acids include SEQ ID NO: 12; andCDR3 has at least five consecutive amino acids of the sequence starting in position 117 and finishing in position 126 of SEQ ID NO:2, wherein said at least five consecutive amino acids include SEQ ID NO:13;and(b) a light-chain variable region being defined by the following formula
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4wherein:FR1, FR2, FR3, and FR4 are each framework regions;CDR1, CDR2, and CDR3 are each complementarity determining regions;wherein:CDR1 has at least five consecutive amino acids of the sequence starting in position 44 and finishing in position 56 of SEQ ID NO:4, wherein said at least five consecutive amino acids include SEQ ID NO: 14;CDR2 has at least five consecutive amino acids of the sequence starting in position 66 and finishing in position 76 of SEQ ID NO:4, wherein said at least five consecutive amino acids include SEQ ID NO:15; andCDR3 has at least five consecutive amino acids of the sequence starting in position 109 and finishing in position 117 of SEQ ID NO:4, wherein said at least five consecutive amino acids include SEQ ID NO:16;and
(ii) it has at least one of the following advantageous properties: it binds to one epitope located between position amino acids 20 to 41 of SEQ ID NO:29; it does not bind to an epitope located between position amino acids 42 to 90 of SEQ ID NO:29, and/or between position amino acids 91 to 104 of SEQ ID NO:29; it does not bind to an epitope located between position amino acids 105 to 199 of SEQ ID NO:29; and it does not bind to an epitope located between position amino acids 200 to 298 of SEQ ID NO:29. |
地址 |
Illkirch Graffenstaden FR |